Ritesh Rathore

Summary

Affiliation: Roger Williams Medical Center
Country: USA

Publications

  1. doi request reprint Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)
    Ritesh Rathore
    Division of Hematology Oncology, Roger Williams Hospital, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Cancer Chemother Pharmacol 66:1013-7. 2010
  2. doi request reprint Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study
    Ritesh Rathore
    Division of Hematology Oncology, Roger Williams Hospital, Providence, Rhode Island 02908, USA
    Am J Clin Oncol 33:43-6. 2010
  3. ncbi request reprint The chronic leukemias: current and novel therapeutic approaches
    Ritesh Rathore
    Adele R Decof Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:240-2. 2003
  4. doi request reprint Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck
    Neal E Ready
    Brown University Oncology Group, Providence, RI, USA
    Am J Clin Oncol 35:6-12. 2012
  5. ncbi request reprint Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer
    James Y Tsai
    Brown University Oncology Group, Providence, Rhode Island, USA
    Am J Clin Oncol 28:329-33. 2005
  6. ncbi request reprint Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004
  7. ncbi request reprint Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53)
    Prakash B Chougule
    Department of Radiation Oncology, Rhode Island Hospital, Providence, Rhode Island, USA
    Head Neck 30:289-96. 2008
  8. ncbi request reprint Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:670-7. 2004
  9. ncbi request reprint Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells
    Lawrence G Lum
    Adele R Decof Cancer Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:247-8. 2003
  10. ncbi request reprint Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
    Ursula Reusch
    Cancer Immunotherapy Program, Adele R Decof Cancer Center, Providence, Rhode Island, USA
    Clin Cancer Res 12:183-90. 2006

Collaborators

Detail Information

Publications13

  1. doi request reprint Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)
    Ritesh Rathore
    Division of Hematology Oncology, Roger Williams Hospital, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Cancer Chemother Pharmacol 66:1013-7. 2010
    ..A phase I study was performed to determine the maximally tolerated dose of carboplatin, ifosfamide, and docetaxel in advanced head and neck cancers...
  2. doi request reprint Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study
    Ritesh Rathore
    Division of Hematology Oncology, Roger Williams Hospital, Providence, Rhode Island 02908, USA
    Am J Clin Oncol 33:43-6. 2010
    ..We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular carcinoma (HCC)...
  3. ncbi request reprint The chronic leukemias: current and novel therapeutic approaches
    Ritesh Rathore
    Adele R Decof Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:240-2. 2003
    ..Significant advances in allogeneic and autologous donor transplantation have increased the patient eligibility pool and reduced the toxicities while improving upon long term survival results...
  4. doi request reprint Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck
    Neal E Ready
    Brown University Oncology Group, Providence, RI, USA
    Am J Clin Oncol 35:6-12. 2012
    ..To perform a phase II trial evaluating dose dense induction chemotherapy for locally advanced head and neck cancer...
  5. ncbi request reprint Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer
    James Y Tsai
    Brown University Oncology Group, Providence, Rhode Island, USA
    Am J Clin Oncol 28:329-33. 2005
    ....
  6. ncbi request reprint Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004
    ..To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu...
  7. ncbi request reprint Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53)
    Prakash B Chougule
    Department of Radiation Oncology, Rhode Island Hospital, Providence, Rhode Island, USA
    Head Neck 30:289-96. 2008
    ..A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer...
  8. ncbi request reprint Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:670-7. 2004
    ..To conduct a phase I study incorporating trastuzumab with paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus...
  9. ncbi request reprint Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells
    Lawrence G Lum
    Adele R Decof Cancer Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:247-8. 2003
  10. ncbi request reprint Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
    Ursula Reusch
    Cancer Immunotherapy Program, Adele R Decof Cancer Center, Providence, Rhode Island, USA
    Clin Cancer Res 12:183-90. 2006
    ..This study combines EGFR-targeting with the non-MHC-restricted cytotoxicity of anti-CD3 activated T cells (ATC) to enhance receptor-directed cytotoxicity...
  11. ncbi request reprint Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells
    Lawrence G Lum
    Immunotherapy and Blood and Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Clin Breast Cancer 4:212-7. 2003
  12. ncbi request reprint Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer
    Howard Safran
    The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Crit Rev Oncol Hematol 43:57-62. 2002
    ..The addition of gemcitabine to paclitaxel and radiation has also demonstrated promising preliminary activity and a phase II study by the RTOG is being initiated...
  13. ncbi request reprint A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma
    Wallace Akerley
    Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
    Cancer 95:2000-5. 2002
    ..We conducted a Phase I study of weekly paclitaxel (P) and carboplatin (C) in patients with advanced malignancies to determine the maximum tolerated dose (MTD) of this combination...